NCT07464145Phase 3Not yet recruiting

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Study sponsor: Relmada Therapeutics, Inc. · RLMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-12Estimated
Enrollment · participants393Estimated
Source updated2026-09-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Sep 2029. After: Dec 2029.

Check registry source